Ultragenyx Stock Performance
| RARE Stock | USD 47.12 0.12 0.25% |
The entity has a beta of 0.71, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Ultragenyx's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ultragenyx is expected to be smaller as well. At this point, Ultragenyx has a negative expected return of -0.29%. Please make sure to validate Ultragenyx's value at risk, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if Ultragenyx performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Ultragenyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.93 | Five Day Return 6.17 | Year To Date Return (1.02) | Ten Year Return 10.04 | All Time Return 12.85 |
Last Split Factor 1:3 | Last Split Date 2014-01-17 |
1 | Tony Kavak And His Private Collection Of The Reference 5970 Part One | 09/03/2024 |
2 | Ultragenyx Announces Upcoming Setrusumab Presentations at the ASBMR 2024 Annual Meeting | 09/26/2024 |
3 | Disposition of 7465 shares by Howard Horn of Ultragenyx at 52.76 subject to Rule 16b-3 | 10/10/2024 |
4 | Research Analysts Updated EPS Estimates for October 22nd | 10/22/2024 |
5 | Ultragenyx Pharmaceutical Inc Q3 2024 Earnings Revenue Surpasses Estimates at 1 ... | 11/05/2024 |
6 | Ultragenyx Pharmaceutical Inc Q3 2024 Earnings Call Highlights Robust Revenue Growth ... | 11/06/2024 |
7 | Ultragenyx Pharmaceutical Inc. Q3 2024 Earnings Call Transcript | 11/07/2024 |
8 | STAND UP TO CANCER COLLABORATES WITH JOHNSON JOHNSON TO EXPLORE TARGETED THERAPIES FOR RARE DISEASE LINKED TO BLOOD CANCERS | 11/11/2024 |
9 | AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 | 11/14/2024 |
10 | HOUSE OF DELAMAIN MARKS 200 YEARS OF EXCELLENCE WITH RELEASE OF LEDITION RARE DU BICENTENAIRE | 11/19/2024 |
11 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 11/20/2024 |
| Begin Period Cash Flow | 137.6 M |
Ultragenyx |
Ultragenyx Relative Risk vs. Return Landscape
If you would invest 5,762 in Ultragenyx on August 27, 2024 and sell it today you would lose (1,038) from holding Ultragenyx or give up 18.01% of portfolio value over 90 days. Ultragenyx is currently does not generate positive expected returns and assumes 1.9288% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Ultragenyx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ultragenyx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ultragenyx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ultragenyx, and traders can use it to determine the average amount a Ultragenyx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1511
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RARE |
Estimated Market Risk
| 1.93 actual daily | 17 83% of assets are more volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ultragenyx is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ultragenyx by adding Ultragenyx to a well-diversified portfolio.
Ultragenyx Fundamentals Growth
Ultragenyx Stock prices reflect investors' perceptions of the future prospects and financial health of Ultragenyx, and Ultragenyx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ultragenyx Stock performance.
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (1.07) % | ||||
| Operating Margin | (0.95) % | ||||
| Current Valuation | 3.77 B | ||||
| Shares Outstanding | 92.34 M | ||||
| Price To Earning | (6.90) X | ||||
| Price To Book | 12.58 X | ||||
| Price To Sales | 8.35 X | ||||
| Revenue | 434.25 M | ||||
| Gross Profit | (370.78 M) | ||||
| EBITDA | (516.45 M) | ||||
| Net Income | (606.64 M) | ||||
| Cash And Equivalents | 542.8 M | ||||
| Cash Per Share | 7.75 X | ||||
| Total Debt | 43.17 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.08 X | ||||
| Book Value Per Share | 3.76 X | ||||
| Cash Flow From Operations | (474.81 M) | ||||
| Earnings Per Share | (6.35) X | ||||
| Market Capitalization | 4.36 B | ||||
| Total Asset | 1.49 B | ||||
| Retained Earnings | (3.39 B) | ||||
| Working Capital | 451.75 M | ||||
| Current Asset | 416.79 M | ||||
| Current Liabilities | 50.43 M | ||||
About Ultragenyx Performance
By analyzing Ultragenyx's fundamental ratios, stakeholders can gain valuable insights into Ultragenyx's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ultragenyx has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ultragenyx has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 274.25 | 260.54 | |
| Return On Tangible Assets | (0.47) | (0.50) | |
| Return On Capital Employed | (0.47) | (0.49) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (2.20) | (2.09) |
Things to note about Ultragenyx performance evaluation
Checking the ongoing alerts about Ultragenyx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ultragenyx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ultragenyx generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 434.25 M. Net Loss for the year was (606.64 M) with loss before overhead, payroll, taxes, and interest of (370.78 M). | |
| Ultragenyx currently holds about 542.8 M in cash with (474.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.75. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 |
- Analyzing Ultragenyx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ultragenyx's stock is overvalued or undervalued compared to its peers.
- Examining Ultragenyx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ultragenyx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ultragenyx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ultragenyx's stock. These opinions can provide insight into Ultragenyx's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ultragenyx Stock analysis
When running Ultragenyx's price analysis, check to measure Ultragenyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ultragenyx is operating at the current time. Most of Ultragenyx's value examination focuses on studying past and present price action to predict the probability of Ultragenyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ultragenyx's price. Additionally, you may evaluate how the addition of Ultragenyx to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |